Guggenheim has reiterated its Buy rating on Summit Therapeutics despite lowering the price target slightly to $38 from $40, indicating confidence in the stock's upside from its current price of $14.98. The positive outlook follows strong Q2 2026 earnings and significant progress with the company's lead drug candidate, ivonescimab, which has received two approvals in China and is involved in 52 global clinical trials. This progress is supported by promising late-stage study results, including the HARMONi-6 study, and over 4,000 patients worldwide receiving the drug. Investors see potential growth as ivonescimab advances in cancer treatment through its dual-action mechanism.
Kuehn Law, PLLC is investigating whether certain officers and directors of Summit Therapeutics Inc. breached their fiduciary duties to shareholders through potential self-dealing. This legal probe could lead to damages for shareholders and reforms in...
Summit Therapeutics reported a wider-than-expected loss and disclosed a 'going concern risk' due to insufficient cash to fund operations for the next year, despite raising over $300 million recently. The company is cutting costs and has $690.7 millio...
